Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines

Prostate

Volumn 73, Issue 13, 2013, Pages 1378-1390

  Seiler, Daniel ^a   Zheng, Junying ^a   Liu, Gentao ^b   Wang, Shunyou ^c   Yamashiro, Joyce ^a   Reiter, Robert E ^a   Huang, Jiaoti ^a   Zeng, Gang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHANGHAI PULMONARY HOSPITAL   (China)

^c Takeda San Diego Inc   (United States)

Author keywords

androgen deprivation; androgen receptor; castration resistance; prostate cancer stem cells

Indexed keywords

ANDROGEN RECEPTOR; BETA ACTIN; CD24 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 8; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CASTRATION RESISTANT PROSTATE CANCER; CELL CLONE; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL RENEWAL; CELL STRAIN LNCAP; CONTROLLED STUDY; DILUTION; DOWN REGULATION; GENE PRODUCT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANDROGEN DEPRIVATION; ANDROGEN RECEPTOR; CASTRATION RESISTANCE; PROSTATE CANCER STEM CELLS;

ANDROGENS; ANIMALS; CASTRATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, SCID; NEOPLASTIC STEM CELLS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; UP-REGULATION;

EID: 84882252233     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22685     Document Type: Article

References (45)

1. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3 (7): 730-737.
2. Al-Hajj M, Clarke MF,. Self-renewal solid tumor stem cells. Oncogene 2004; 23 (43): 7274-7282.
3. Uchida N, Weissman IL,. Searching for hematopoietic stem cells: Evidence that Thy-1.1lo Lin- Sca-1+ cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow. J Exp Med 1992; 175 (1): 175-184.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100 (7): 3983-3988.
5. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB,. Identification of human brain tumor initiating cells. Nature 2004; 432 (7015): 396-401.
6. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE,. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104 (3): 973-978.
7. Chen L, Kasai T, Li Y, Sugii Y, Jin G, Okada M, Vaidyanath A, Mizutani A, Satoh A, Kudoh T, Hendrix MJ, Salomon DS, Fu L, Seno M,. A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS One 2012; 7 (4): e33544.
8. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG,. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 2005; 65 (14): 6207-6219.
9. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65 (23): 10946-10951.
10. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG,. Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+ alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007; 67 (14): 6796-6805.
11. Lang SH, Sharrard RM, Stark M, Villette JM, Maitland NJ,. Prostate epithelial cell lines form spheroids with evidence of glandular differentiation in three-dimensional matrigel cultures. Br J Cancer 2001; 85 (4): 590-599.
12. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39.
13. Craft N, Shostak Y, Carey M, Sawyers CL,. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5 (3): 280-285.
14. Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Kong X, Melamed J, Fang S, Xiao Z, Veenstra TD, Qiu Y,. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 2009; 15 (4): 270-282.
15. Debes JD, Tindall DJ,. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351 (15): 1488-1490.
16. Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS,. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system. Prostate 2003; 55 (4): 299-307.
17. Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM,. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004; 91 (4): 671-683.
18. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM,. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009; 461 (7263): 495-500.
19. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L,. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res 2012; 72 (2): 527-536.
20. Tang Y, Hamburger AW, Wang L, Khan MA, Hussain A,. Androgen deprivation and stem cell markers in prostate cancers. Int J Clin Exp Pathol 2009; 3 (2): 128-138.
21. Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG, Williams ED, Thalmann GN,. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 2012; 30 (6): 1076-1086.
22. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C,. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012; 22 (3): 373-388.
23. Beier D, Schulz JB, Beier CP,. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 2011; 10: 128.
24. Rasheed ZA, Kowalski J, Smith BD, Matsui W,. Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011; 29 (6): 883-887.
25. Takebe N, Harris PJ, Warren RQ, Ivy SP,. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8 (2): 97-106.
26. Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF,. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000; 165 (2): 1153-1159.
27. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H,. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4 (3): 209-221.
28. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS,. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003; 55 (1): 71-80.
29. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Li H, Palapattu GS, Pang S, Lin K, Huang J, Ivanov I, Li W, Suraneni MV, Tang DG,. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012; 10 (5): 556-569.
30. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II, Thomson JA,. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318 (5858): 1917-1920.
31. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S,. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131 (5): 861-872.
32. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE,. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439 (7072): 84-88.
33. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ, Tang DG,. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009; 27 (5): 993-1005.
34. Isaacs JT, Coffey DS,. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the dunning R-3327-H adenocarcinoma. Cancer Res 1981; 41 (12 Pt 1): 5070-5075.
35. Isaacs JT, Schulze H, Coffey DS,. Development of androgen resistance in prostatic cancer. Prog Clin Biol Res 1987; 243A: 21-31.
36. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL,. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999; 59 (19): 5030-5036.
37. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM,. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57 (21): 4687-4691.
38. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS,. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57 (3): 205-225.
39. Kondo T, Setoguchi T, Taga T,. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101 (3): 781-786.
40. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD, Greenberg NM,. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and co-factor dependent activities in autochthonous prostate cancer. J Biol Chem 2001; 276 (14): 11204-11213.
41. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM,. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 2005; 102 (4): 1151-1156.
42. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP,. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43 (4): 1809-1818.
43. Pascal LE, Vencio RZ, Vessella RL, Ware CB, Vencio EF, Denyer G, Liu AY,. Lineage relationship of prostate cancer cell types based on gene expression. BMC Med Genomics 2011; 4: 46.
44. Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VA, George NJ, Clarke NW,. Characterization of benign and malignant prostate epithelial Hoechst 33,342 side populations. Prostate 2007; 67 (13): 1384-1396.
45. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B,. Cancer/testis antigen expression in human mesenchymal stem cells: Down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005; 65 (6): 2207-2215.